• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Higher, but Not Too High, Dose Is Only One Determinant of Corticosteroid Treatment Success in Severe COVID-19.

作者信息

Salton Francesco, Confalonieri Paola, Torregiani Chiara, Ruaro Barbara, Confalonieri Marco

机构信息

University of Trieste Trieste, Italy.

出版信息

Ann Am Thorac Soc. 2023 Sep;20(9):1371. doi: 10.1513/AnnalsATS.202304-329LE.

DOI:10.1513/AnnalsATS.202304-329LE
PMID:37343288
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10502891/
Abstract
摘要

相似文献

1
Higher, but Not Too High, Dose Is Only One Determinant of Corticosteroid Treatment Success in Severe COVID-19.较高但不过高的剂量只是重症 COVID-19 中皮质类固醇治疗成功的一个决定因素。
Ann Am Thorac Soc. 2023 Sep;20(9):1371. doi: 10.1513/AnnalsATS.202304-329LE.
2
Reply: Higher, but Not Too High, Dose Is Only One Determinant of Corticosteroid Treatment Success in Severe COVID-19.回复：更高但不过高的剂量只是重症COVID-19中皮质类固醇治疗成功的一个决定因素。
Ann Am Thorac Soc. 2023 Sep;20(9):1372. doi: 10.1513/AnnalsATS.202305-436LE.
3
Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study.糖皮质激素治疗住院严重 COVID-19 患者的疗效：一项多中心研究。
Clin Microbiol Infect. 2021 Jan;27(1):105-111. doi: 10.1016/j.cmi.2020.09.014. Epub 2020 Sep 22.
4
Comparison of pulse-dose and high-dose corticosteroids with no corticosteroid treatment for COVID-19 pneumonia in the intensive care unit.比较 ICU 中 COVID-19 肺炎患者的脉冲剂量和高剂量皮质类固醇与无皮质类固醇治疗。
J Med Virol. 2022 Jan;94(1):349-356. doi: 10.1002/jmv.27351. Epub 2021 Sep 28.
5
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?静脉注射皮质类固醇冲击是否优于小剂量皮质类固醇治疗重症 COVID-19 患者？
Eur Respir J. 2022 Oct 20;60(4). doi: 10.1183/13993003.01220-2022. Print 2022 Oct.
6
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial - Authors' reply.新冠疫情中高剂量皮质类固醇疗法：RECOVERY试验——作者回复
Lancet. 2024 Apr 6;403(10434):1339-1340. doi: 10.1016/S0140-6736(23)02879-9.
7
Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis.糖皮质激素治疗非重症 COVID-19 肺炎的效果：基于倾向评分的分析。
Shock. 2020 Nov;54(5):638-643. doi: 10.1097/SHK.0000000000001574.
8
The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis.COVID-19 感染患者中皮质类固醇治疗的比例和效果：系统评价和荟萃分析。
PLoS One. 2021 Apr 21;16(4):e0249481. doi: 10.1371/journal.pone.0249481. eCollection 2021.
9
Adjuvant corticosteroid therapy for critically ill patients with COVID-19.COVID-19重症患者的辅助性皮质类固醇治疗
Crit Care. 2020 May 19;24(1):241. doi: 10.1186/s13054-020-02964-w.
10
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet.为 COVID-19 患者制定皮质类固醇治疗方案：尚未成功。
Eur Respir J. 2023 Apr 20;61(4). doi: 10.1183/13993003.00270-2023. Print 2023 Apr.

引用本文的文献

1
Theory and Practice of Glucocorticoids in COVID-19: Getting to the Heart of the Matter-A Critical Review and Viewpoints.糖皮质激素在新冠疫情中的理论与实践：直击核心——批判性综述与观点
Pharmaceuticals (Basel). 2023 Jun 25;16(7):924. doi: 10.3390/ph16070924.

本文引用的文献

1
Higher- versus Lower-Dose Corticosteroids for Severe to Critical COVID-19: A Systematic Review and Dose-Response Meta-analysis.高剂量与低剂量皮质类固醇治疗重症至危重新冠肺炎：系统评价和剂量反应荟萃分析。
Ann Am Thorac Soc. 2023 Apr;20(4):596-604. doi: 10.1513/AnnalsATS.202208-720OC.
2
Prolonged higher dose methylprednisolone conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS).COVID-19 肺炎中较长时间的高剂量甲泼尼龙与常规地塞米松的随机对照试验（MEDEAS）。
Eur Respir J. 2023 Apr 20;61(4). doi: 10.1183/13993003.01514-2022. Print 2023 Apr.
3
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial.静脉注射甲基强的松龙脉冲治疗住院严重 COVID-19 肺炎患者：一项双盲、随机、安慰剂对照试验。
Eur Respir J. 2022 Oct 20;60(4). doi: 10.1183/13993003.00025-2022. Print 2022 Oct.
4
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial.地塞米松 12 毫克与 6 毫克对 COVID-19 合并严重低氧血症成人患者存活无生命支持天数的影响：COVID 类固醇 2 随机试验。
JAMA. 2021 Nov 9;326(18):1807-1817. doi: 10.1001/jama.2021.18295.
5
Systemic corticosteroids for the treatment of COVID-19.全身性皮质类固醇治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Aug 16;8(8):CD014963. doi: 10.1002/14651858.CD014963.
6
Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS.指导 ARDS 患者长期使用糖皮质激素治疗的药理学原则。
Intensive Care Med. 2020 Dec;46(12):2284-2296. doi: 10.1007/s00134-020-06289-8. Epub 2020 Nov 4.